Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Juvenile Idiopathic Arthritis (JIA) Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Quantification & Classification of Inflammatory Cells in Uveitis Using OCT

NCT07065747
View directory record Official record
Conditions
Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
5 Years to 85 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Jul 21, 2026, 6:29 PM EDT
Completed Phase 4 Interventional

Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA

NCT00792233
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Withdrawal of anti-TNF therapy
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years to 20 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Jul 21, 2026, 6:29 PM EDT
Completed Phase 3 Interventional Results available

Pediatric Arthritis Study of Certolizumab Pegol

NCT01550003
View directory record Official record
Conditions
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Interventions
Certolizumab Pegol (CZP)
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Jul 21, 2026, 6:29 PM EDT
Completed No phase listed Observational Results available

Start Time Optimization of Biologics in Polyarticular JIA

NCT02593006
View directory record Official record
Conditions
Polyarticular Juvenile Rheumatoid Arthritis, Arthritis, Juvenile Idiopathic
Interventions
Not listed
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
2 Years to 18 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
52
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Jul 21, 2026, 6:29 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults

NCT00534495
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Rilonacept
Biological
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Months to 19 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Jul 21, 2026, 6:29 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

NCT01803321
View directory record Official record
Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
rilonacept (IL-1 Trap), Placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
4 Years to 20 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Los Angeles, California • Wilmington, Delaware • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2013 · Synced Jul 21, 2026, 6:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers

NCT01358383
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
naproxen, esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Jul 21, 2026, 6:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Yoga Therapy for Adolescents With Juvenile Idiopathic Arthritis

NCT03286933
View directory record Official record
Conditions
Adolescent Juvenile Idiopathic Arthritis, Yoga Therapy
Interventions
yoga
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
14 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Jul 21, 2026, 6:29 PM EDT
Terminated Phase 2 Interventional Results available

Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) in JIA

NCT05710640
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
Active tcVNS, Sham tcVNS
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
San Francisco, California • Orlando, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 21, 2026, 6:29 PM EDT
Completed Phase 1 Interventional

Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis

NCT02165345
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 18 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
9
States / cities
Little Rock, Arkansas • Chicago, Illinois • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Jul 21, 2026, 6:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Juvenile Rheumatoid Arthritis Research Registry

NCT00090571
View directory record Official record
Conditions
Juvenile Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Jul 21, 2026, 6:29 PM EDT
Completed Phase 4 Interventional Results available

A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects

NCT00807846
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid
Interventions
Celecoxib, Naproxen
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
18
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jul 21, 2026, 6:29 PM EDT
Completed Phase 3 Interventional

Supplementation With Vitamin D, Calcium or Both on Calcium Absorption and Bone Mineral Content in Children With JRA

NCT00570934
View directory record Official record
Conditions
Juvenile Rheumatoid Arthritis
Interventions
Cholecalciferol, Calcium, Calcium and cholecalciferol, Placebo
Dietary Supplement · Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
3 Years to 15 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 9, 2016 · Synced Jul 21, 2026, 6:29 PM EDT
Active, not recruiting No phase listed Observational

An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis

NCT01357668
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Up to 17 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2029
U.S. locations
3
States / cities
Little Rock, Arkansas • Princeton, New Jersey • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jul 21, 2026, 6:29 PM EDT
Recruiting Phase 3 Interventional

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

NCT05609630
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Upadacitinib, Tocilizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
1 Year to 17 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Valhalla, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 21, 2026, 6:29 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 21, 2026, 6:29 PM EDT
Completed Phase 4 Interventional Results available

Adalimumab in JIA-associated Uveitis Stopping Trial

NCT03816397
View directory record Official record
Conditions
Uveitis, JIA
Interventions
Adalimumab, Placebo
Biological · Other
Lead sponsor
Nisha Acharya
Other
Eligibility
2 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Sacramento, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Jul 21, 2026, 6:29 PM EDT
Completed No phase listed Observational

Use of Thermal and 3D Imaging to Quantify Arthritis

NCT01044823
View directory record Official record
Conditions
Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis
Interventions
3D and thermal imaging
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
4 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Jul 21, 2026, 6:29 PM EDT
Terminated No phase listed Observational Results available

Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis

NCT00688545
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid
Interventions
Celecoxib, nsNSAIDs
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
27
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Washington D.C., District of Columbia + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jul 21, 2026, 6:29 PM EDT
Withdrawn Phase 2 Interventional

HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis

NCT06623240
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
allogeneic Hope Biosciences adipose-derived mesenchymal stem cells, Normal Saline Solution 0.9%
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
2 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 21, 2026, 6:29 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

NCT06869551
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
5 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Lancaster, California • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 21, 2026, 6:29 PM EDT
Completed Early Phase 1 Interventional

Human Factors Study of Methotrexate Prefilled Pen (50 mg/mL) in Patients With Juvenile Idiopathic Arthritis

NCT02052167
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
methotrexate prefilled pen
Device
Lead sponsor
medac GmbH
Industry
Eligibility
2 Years to 20 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Jul 21, 2026, 6:29 PM EDT
Not yet recruiting Phase 4 Interventional

Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial

NCT07699107
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, Anterior
Interventions
Adalimumab/Biosimilar
Biological
Lead sponsor
Nisha Acharya
Other
Eligibility
2 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
9
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 21, 2026, 6:29 PM EDT
Completed Phase 2 Interventional

Calcium Supplements for Bone Health in Juvenile Rheumatoid Arthritis

NCT00000429
View directory record Official record
Conditions
Juvenile Rheumatoid Arthritis
Interventions
Calcium carbonate
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 18 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Jul 21, 2026, 6:29 PM EDT